If you want to make your Schedule 1 experience a lot more convenient, exciting, or faster-paced, we’ve got a bunch of mods ...

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), with a price target of $39.00. The company’s shares ...

TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $12.50.

Here’s how it works. Rocket Lab has launched its workhorse Electron rocket for the third time in two weeks. The New Zealand-based company successfully launched eight wildfire detection ...

This week, when the NBA's board of governors meets in New York, team owners will discuss a proposal to launch a new basketball league in Europe, according to Sportico. In January, NBA commissioner ...

NASDAQ:KALV opened at $12.07 on Friday. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The company has a market cap of $600.07 million, a P/E ratio of -3.32 and ...

This year is no different with many teams introducing some fun, unique and weird menu items. In many cases, teams have taken those classic ballpark foods like hot dogs, fries and burgers and put a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A Ukrainian rocket attack killed six people, including three Russian state media workers, in eastern Ukraine’s Russian-occupied Luhansk region, according to Russian news organisations and officials.

As of 11:53:22 AM EDT. Market Open. CAMBRIDGE, Mass. & SALISBURY, England, March 25, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open ...